BioSyent Inc. (TSXV:RX)
Canada · Delayed Price · Currency is CAD 11.95
-0.19 (-1.57%)
Dec 1, 2025, 1:22 PM EST
BioSyent Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 42.18 | 35.03 | 31.59 | 27.93 | 28.62 | 22.33 | Upgrade | |
Revenue Growth (YoY) | 22.22% | 10.89% | 13.13% | -2.42% | 28.15% | 4.24% | Upgrade |
Cost of Revenue | 9.51 | 7.17 | 5.99 | 5.07 | 5.98 | 4.91 | Upgrade |
Gross Profit | 32.67 | 27.86 | 25.6 | 22.86 | 22.64 | 17.42 | Upgrade |
Selling, General & Admin | 21.27 | 18.67 | 18.13 | 15.88 | 14.45 | 12.39 | Upgrade |
Operating Expenses | 21.27 | 18.67 | 18.13 | 15.88 | 14.45 | 12.39 | Upgrade |
Operating Income | 11.4 | 9.18 | 7.47 | 6.98 | 8.18 | 5.03 | Upgrade |
Interest Expense | -0.05 | -0.06 | -0.07 | -0.08 | -0.09 | -0.09 | Upgrade |
Interest & Investment Income | 0.88 | 1.09 | 1.13 | 0.53 | 0.16 | 0.26 | Upgrade |
Currency Exchange Gain (Loss) | - | - | - | - | - | 0.04 | Upgrade |
EBT Excluding Unusual Items | 12.23 | 10.21 | 8.53 | 7.43 | 8.25 | 5.24 | Upgrade |
Asset Writedown | -0.43 | -0.43 | - | - | - | - | Upgrade |
Other Unusual Items | - | - | - | - | 0.13 | - | Upgrade |
Pretax Income | 11.8 | 9.78 | 8.53 | 7.43 | 8.38 | 5.24 | Upgrade |
Income Tax Expense | 3.17 | 2.51 | 2.07 | 1.97 | 2.1 | 1.44 | Upgrade |
Net Income | 8.63 | 7.27 | 6.46 | 5.46 | 6.28 | 3.8 | Upgrade |
Net Income to Common | 8.63 | 7.27 | 6.46 | 5.46 | 6.28 | 3.8 | Upgrade |
Net Income Growth | 21.47% | 12.54% | 18.35% | -13.11% | 65.51% | -13.14% | Upgrade |
Shares Outstanding (Basic) | 11 | 12 | 12 | 12 | 13 | 13 | Upgrade |
Shares Outstanding (Diluted) | 12 | 12 | 12 | 13 | 13 | 13 | Upgrade |
Shares Change (YoY) | -2.73% | -2.98% | -2.95% | -2.57% | -1.70% | -6.10% | Upgrade |
EPS (Basic) | 0.76 | 0.63 | 0.54 | 0.44 | 0.50 | 0.29 | Upgrade |
EPS (Diluted) | 0.75 | 0.62 | 0.53 | 0.43 | 0.49 | 0.29 | Upgrade |
EPS Growth | 24.83% | 16.01% | 22.07% | -10.86% | 68.28% | -6.45% | Upgrade |
Free Cash Flow | 8.1 | 8.63 | 5 | 4.9 | 4.59 | 6.88 | Upgrade |
Free Cash Flow Per Share | 0.70 | 0.73 | 0.41 | 0.39 | 0.36 | 0.53 | Upgrade |
Dividend Per Share | 0.195 | 0.180 | 0.160 | 0.040 | - | - | Upgrade |
Dividend Growth | 11.43% | 12.50% | 300.00% | - | - | - | Upgrade |
Gross Margin | 77.46% | 79.52% | 81.03% | 81.85% | 79.10% | 78.02% | Upgrade |
Operating Margin | 27.04% | 26.21% | 23.65% | 25.00% | 28.59% | 22.52% | Upgrade |
Profit Margin | 20.47% | 20.75% | 20.45% | 19.55% | 21.95% | 16.99% | Upgrade |
Free Cash Flow Margin | 19.22% | 24.64% | 15.81% | 17.55% | 16.04% | 30.81% | Upgrade |
EBITDA | 11.98 | 9.6 | 7.63 | 7.26 | 8.47 | 5.37 | Upgrade |
EBITDA Margin | 28.40% | 27.41% | 24.15% | 26.01% | 29.60% | 24.04% | Upgrade |
D&A For EBITDA | 0.58 | 0.42 | 0.16 | 0.28 | 0.29 | 0.34 | Upgrade |
EBIT | 11.4 | 9.18 | 7.47 | 6.98 | 8.18 | 5.03 | Upgrade |
EBIT Margin | 27.04% | 26.21% | 23.65% | 25.00% | 28.59% | 22.52% | Upgrade |
Effective Tax Rate | 26.85% | 25.68% | 24.30% | 26.54% | 25.03% | 27.53% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.